pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,605 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1605Endpoints1257BioSpace587Fierce Biotech585BioPharma Dive474raps199onclive165fda recalls105fda medwatch
therapy area
allOncology10896Rare Disease2804Immunology2568Cardiology2302Pulmonology1918Hematology1912Vaccines1659Psychiatry & CNS
  • Federal alcohol study finds low-level drinking may raise disease risk, faces political pushback
    STAT’s Morning Rounds reported that a federally commissioned study on alcohol’s health effects was published today in an independent journal. The researchers concluded that even modest alcohol cons…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Trump administration threatens fines for over 500 hospitals that fail to disclose pricing
    The Trump administration has warned more than 500 hospitals that they are not providing the public with basic pricing information, the Associated Press reported. Hospitals that fail to create a pl…
    STAT · 4mo agoRegulatoryNegative↗ source
← prev
page 49 of 65
next →
95
globenewswire health73
fda press55
1111
Ophthalmology883
Endocrinology & Metabolism699
Pain678
Nephrology676
  • NIH names John Powers III as acting director of NIAID amid leadership uncertainty
    The National Institutes of Health has appointed researcher John Powers III to serve as acting director of the National Institute of Allergy and Infectious Diseases (NIAID). Powers previously served…
    STAT · 4mo agoNeutral↗ source
  • Oura and Whoop add in-app virtual doctor visits, moving wearable data toward clinical use
    Wearable makers Oura and Whoop announced that users will soon be able to connect with doctors through their apps, allowing virtual consultations when a device flags a health concern. The new featu…
    STAT · 4mo agoNeutral↗ source
  • Trump-suppressed alcohol health study released, finds low-level drinking may raise disease risk
    A federal study on alcohol's health effects, commissioned by SAMHSA in 2023 to inform U.S. dietary guidelines, has finally been published in a scientific journal after being withheld by the Trump a…
    STAT · 4mo agoRegulatoryNegative↗ source
  • NIH staff say leadership ignored dissent letter a year after Bethesda Declaration
    A new report released on the one‑year anniversary of the Bethesda Declaration says NIH leadership has largely ignored the concerns raised by staff in their open letter of dissent. The report, titl…
    STAT · 4mo agoNegative↗ source
  • STAT chooses to keep health care as two words despite AP stylebook shift
    The Associated Press updated its style guide in April, merging health care into the single word healthcare. The change sparked discussion among journalists and readers. At STAT, the editorial staf…
    STAT · 4mo agoNeutral↗ source
  • J&J to buy Firefly Bio for $1 billion to boost KRAS inhibitor program
    J&J announced Monday it will acquire biotech startup Firefly Bio for $1 billion, aiming to broaden its KRAS inhibitor portfolio. The move follows recent data from Revolution Medicines showing a KR…
    STAT · 4mo agoDealPositive↗ source
  • Financing gaps keep $2 million gene therapies out of reach for many patients
    William Padula argues that the United States lacks the financial infrastructure to deliver ultra‑expensive gene therapies, even though they can cure diseases with a single dose. He notes that treat…
    STAT · 4mo agoNegative↗ source
  • Lilly shares safety data on next-gen obesity drug retatrutide; Revolution Medicines reports strong pancreatic cancer results
    Lilly provided new data that detail the safety and tolerability profile of its next-generation obesity therapy, retatrutide. The information adds to the growing body of evidence supporting the drug…
    STAT · 4mo agoPositive readoutPositive↗ source
  • AstraZeneca’s oral GLP-1 candidate elecoglipron cuts weight 11% in Phase 2 obesity trial
    A Phase 2 study (VISTA) of AstraZeneca’s oral GLP‑1 molecule elecoglipron in people with obesity showed an average weight loss of 11.2 % after 36 weeks, according to data presented at the American…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Congo Ebola frontline health workers face low pay and exhaustion amid outbreak
    Dr. Richard Lokudu, medical director of Mongbwalu General Referral Hospital, says he and his colleagues are receiving almost no compensation while treating patients in the current Ebola outbreak.…
    STAT · 4mo agoNegative↗ source
  • Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisition
    Novo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential. Revolution Medicines and Tango Therapeutics reported a high response…
    STAT · 4mo agoNeutral↗ source
  • Tango and Revolution report high response rates in early pancreatic cancer combo trial
    Tango Therapeutics and Revolution Medicines tested a combination of Tango's drug vopimetostat with Revolution's daraxonrasib in an early-stage clinical trial for pancreatic cancer. The study enroll…
    STAT · 4mo agoPositive readoutPositive↗ source
  • UnitedHealthcare reduces reimbursement for lactation counseling, sparking provider backlash
    UnitedHealthcare announced a change to its payment policy for lactation counseling services. The new policy would lower or eliminate reimbursement for many providers who offer these services, prom…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Mass General launches mobile vascular clinic to treat unhoused patients and prevent amputations
    Unhoused individuals often face untreated vascular problems that can quickly lead to severe wounds and the risk of losing a limb. Limited access to regular medical care leaves many without timely i…
    STAT · 4mo agoPositive↗ source
  • ADA conference sees data presentations and police escort of members over editorial distribution
    The American Diabetes Association held its annual meeting in New Orleans, concluding three days of sessions that featured new data readouts and scientific presentations. Attendees heard updates on…
    STAT · 4mo agoNeutral↗ source
  • U.S. horses face obesity epidemic mirroring human rates
    A recent peer‑reviewed study found that about 51% of mature light‑breed horses in the United States are obese, a prevalence that ranks among the world’s highest and exceeds rates in Britain, Austra…
    STAT · 4mo agoNegative↗ source
  • Boehringer’s obesity drug cuts liver fat but lags behind competitors in weight loss
    Data from a Phase 3 trial of Boehringer Ingelheim’s weekly injectable survodutide were presented at the American Diabetes Association meeting. Patients receiving the highest dose lost about 13% of…
    STAT · 4mo agoNegative readoutNegative↗ source
  • STAT roundup highlights obesity drug competition and other ADA conference updates
    STAT's ADA in 30 Seconds newsletter offers a brief snapshot of the American Diabetes Association's annual meeting, covering a range of topics for readers. Elaine Chen notes that the market for obe…
    STAT · 4mo agoNeutral↗ source
  • Lilly presents safety data on obesity drug retatrutide, noting rare cardiac events
    Eli Lilly reported new safety and tolerability findings for its next-generation obesity therapy retatrutide at the American Diabetes Association annual meeting. In the study, 7 of the 403 particip…
    STAT · 4mo agoNegative readoutNeutral↗ source
  • Pfizer’s monthly obesity drug berobenatide shows up to 12% weight loss in mid-stage VESPER-3 study
    Detailed data from Pfizer's mid‑stage VESPER-3 trial indicate that the company’s monthly‑dosed obesity candidate, berobenatide, continues to demonstrate weight‑loss potential. The drug, originally…
    STAT · 4mo agoPositive readoutNeutral↗ source
  • Former CDC director warns that new Ebola outbreak in DRC requires massive, immediate action
    Tom Frieden, who led the U.S. CDC response to the 2014‑2016 West Africa Ebola epidemic that killed more than 11,000 people, writes about the new crisis in the Democratic Republic of the Congo. He…
    STAT · 4mo agoNegative↗ source
  • ADA conference spotlights triple hormone receptors, a monthly obesity drug and mixed outcomes
    The American Diabetes Association’s annual meeting in New Orleans featured updates on emerging diabetes therapies. Speakers highlighted research on drugs that target three hormone receptors simulta…
    STAT · 4mo agoNeutral↗ source
  • Growing Amish population poses unique public health challenges, says STAT opinion piece
    The First Opinion podcast explored how the expanding Amish community impacts public health, noting that the group may approach 2 million people in the United States by 2075. While some political fi…
    STAT · 4mo agoNeutral↗ source